Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.
The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 +/- 1.2 h, and that of tazobactam was 5.6 +/- 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.
Mueller
Silke C
SC
Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Rostock, D-18057 Rostock, Germany. silke.mueller@med.uni-rostock.de
Majcher-Peszynska
Jolanta
J
Hickstein
Heiko
H
Francke
Astrid
A
Pertschy
Annette
A
Schulz
Martin
M
Mundkowski
Ralf
R
Drewelow
Bernd
B
D000328:Adult; D000368:Aged; D001002:Anuria / Q000628:therapy*; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010878:Piperacillin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D006435:Renal Dialysis / Q000379:methods*
D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin